| 英文摘要 |
Since 2000, Taiwan has implemented the Drug Injury Relief Act to provide timely redress for individuals harmed by the legitimate use of approved medications and to enhance drug safety. This study examines the relationship between drug injury relief and the right to health by adopting a documentary research approach, analysing Taiwan’s legislative background and risk management policies. It also systematically reviews periodic reports submitted by Sweden, Germany, Japan, and South Korea, in light of relevant international human rights standards. The findings reveal divergent interpretations of the legal status of Taiwan’s drug injury relief system among key stakeholders. While administrative authorities regard it as a vital policy for safeguarding both the right to health and the right to remedy, legislators, and the Drug Injury Relief Review Committee, though consistent with international human rights principles, have never explicitly invoked the right to health. The Constitutional Court, on the other hand, frames the system as social welfare, potentially narrowing its scope under the human rights framework. Although drug injury relief may not constitute a core obligation under the right to health as interpreted by the Committee on Economic, Social and Cultural Rights, it nonetheless plays a significant role in progressively realising this right. In particular, the system contributes to drug safety through risk prevention, health education, and compensatory mechanisms. Taiwan is also distinctive in being the only country to explicitly frame drug injury relief as part of its national human rights reporting. In this view, the government should clarify the normative positioning of the institution within its broader human rights commitments to strengthen its legitimacy and policy coherence. |